We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+4.37%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.14B
AUM Growth
+$113M
Cap. Flow
+$131M
Cap. Flow %
11.52%
Top 10 Hldgs %
48.07%
Holding
60
New
9
Increased
13
Reduced
15
Closed
3

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$33.5M
2
ARRY
Array Biopharma Inc
ARRY
+$24.8M
3
ACIU icon
AC Immune
ACIU
+$20.3M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$16.8M
5
REPL icon
Replimune Group
REPL
+$16M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$11.6M
2
ARQL
Arqule Inc
ARQL
+$9.22M
3
ANAB icon
AnaptysBio
ANAB
+$7.05M
4
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$5.91M
5
FBRX icon
Forte Biosciences
FBRX
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGLS
51
DELISTED
Regulus Therapeutics
RGLS
$2.7M 0.24%
114,043
– –
KDNY
52
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.12M 0.19%
57,555
-1,638
-3% -$52.6K
FRTX
53
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.83M 0.16%
4,230
– –
EPIX
54
DELISTED
ESSA Pharma
EPIX
$1.73M 0.15%
576,771
+23,980
+4% +$80.2K
RLM
55
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$1.17M 0.1%
+360,866
New +$1.55M
LOXO
56
DELISTED
Loxo Oncology, Inc
LOXO
$699K 0.06%
4,089
– –
ZYME icon
57
Zymeworks
ZYME
$1.64B
$311K 0.03%
19,804
– –
FBRX icon
58
Forte Biosciences
FBRX
$1.57B
– –
-1,256
Closed -$4.4M
IRWD icon
59
Ironwood Pharmaceuticals
IRWD
$640M
– –
-724,418
Closed -$11.6M
ONCT
60
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-2,758
Closed -$5.91M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2018 Portfolio in Review

As of Q3 2018, BVF Inc held 60 positions worth $1.14B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $131M of net new capital in Q3 2018, opening 9 new positions and adding to 13 existing holdings. Its largest new stake was AC Immune: 2,017,500 shares worth $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Arqule Inc, an estimated $9.22M trimmed.

  • BVF Inc's largest Q3 2018 buy was AC Immune: 2,017,500 shares worth $16.1M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q3 2018, an estimated $33.5M increase.
  • BVF Inc's biggest Q3 2018 reduction was Arqule Inc, cutting an estimated $9.22M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q3 2018, selling an estimated $11.6M.
  • BVF Inc's ten largest holdings make up 48% of its $1.14B portfolio in Q3 2018.
  • BVF Inc opened 9 new positions and closed 3 in Q3 2018.
  • BVF Inc's portfolio value rose 11% quarter-over-quarter to $1.14B.

Based on BVF Inc's 13F filing for Q3 2018, filed 14 Nov 2018.